Fred Aslan - 17 Oct 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Signature
/s/ Neha Krishnamohan, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
17 Oct 2025
Net transactions value
-$153,000
Form type
4
Filing time
17 Oct 2025, 20:44:06 UTC
Previous filing
18 Aug 2025
Next filing
17 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aslan Fred President and CEO, Director C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO /s/ Neha Krishnamohan, Attorney-in-Fact 17 Oct 2025 0001909362

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Sale $153,000 -25,500 -6.7% $6.00 356,721 17 Oct 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.